Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2025-06-04 Investor Presentation
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes Technologies to present at Handelsbanken Small & Mid Cap Seminar 2025 - Attachment: Handelsbanken_June_4_2025.pdf
Investor Presentation Classification · 98% confidence The document is a presentation titled 'Nordic Small & Mid Cap Seminar 2025' delivered by the CEO and CFO. It contains slides detailing company overview, financials (Sales 2023/2024, cash reserves), market segments (Biomanufacturing, Molecular Tools), strategic priorities, customer updates (Q1 2025), CDMO opportunities, future portfolio expansion (RNA therapeutics), and an outlook for 2025. This structure is characteristic of an Investor Presentation (IP) used to communicate strategy and performance to potential and current investors, often given at conferences or roadshows, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses strictly on period results.
2025-06-04 English
ArcticZymes Technologies to present at Handelsbanken Small & Mid Cap Seminar 2025
Report Publication Announcement Classification · 99% confidence The document text is very short (580 characters) and announces that ArcticZymes Technologies will present at the Handelsbanken Small & Mid Cap Seminar 2025. Crucially, it states, 'Please find the presentation enclosed'. This indicates the document itself is an announcement about an upcoming presentation, not the presentation material (IP) or a formal regulatory filing. Since the document is announcing an event where a presentation will be given, and it is not a standard regulatory report, it fits best under the general category for announcements or investor-related communications that don't fit a more specific code. Given the options, this is an announcement related to investor relations/events. While 'IP' (Investor Presentation) is related, this document is the *announcement* of the presentation, not the presentation itself. The 'RPA' (Report Publication Announcement) definition is for announcing the publication of reports (like 10-K, IR). Since this is an announcement about an investor seminar presentation, and it doesn't fit the strict definition of RPA, the most appropriate general category for an announcement of an investor event, especially when the actual presentation material is 'enclosed' (implying this is just the notice), is often categorized under general regulatory/investor announcements if a more specific event code isn't available. However, looking closely at the definitions, there is no specific code for 'Investor Event Announcement'. Given the context of presenting information to investors, and the document being a brief notice, it is closest to a general announcement. Since it is not a formal report publication (RPA) or a standard regulatory filing (RNS), and it relates to investor engagement, I will classify it as RNS as the fallback for miscellaneous investor announcements that don't fit the specific report/financial codes, or consider if it implies an Investor Presentation (IP) is attached. Since the text explicitly mentions 'presentation enclosed', it strongly suggests the actual presentation material is attached, making this document the announcement of that material's availability. If the attached material is the presentation, this document is the announcement of it. Given the lack of a specific 'Event Announcement' code, and the document being a brief notice about an investor-facing activity, RNS (Regulatory Filings - fallback) is the safest general classification for non-standard announcements, although it is very close to an announcement of an Investor Presentation (IP). I will lean towards RNS as the most general fit for an announcement that isn't explicitly a report publication (RPA).
2025-06-04 English
ArcticZymes Technologies AS - Mandatory notification of trade - Attachment: Notification_trading_Marit_Sjo_Lorentzen_2.pdf
Director's Dealing Classification · 100% confidence The document is titled "Notification and public disclosure of transactions by primary insider". It details a transaction (Purchase of shares) made by an individual identified as a 'VP Operations/ primary insider' in the company ArcticZymes Technologies ASA. This type of filing specifically reports personal share transactions by company directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS).
2025-06-04 English
ArcticZymes Technologies AS - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'ArcticZymes Technologies AS - Mandatory notification of trade' and explicitly states that a VP Operations purchased shares. It references disclosure requirements under EU Regulation 596/2014 (Market Abuse Regulation) and the Norwegian Securities Trading Act. This content directly corresponds to reporting personal share transactions by company directors or executives (insider trades), which matches the definition for Director's Dealing (DIRS). The document is short and is a notification of a trade, not a comprehensive annual or quarterly report.
2025-06-04 English
ArcticZymes and Austrian Centre of Industrial Biotechnology Extend Collaborative Research on use of Salt-Active Nucleases for Bionanoparticle Purification - Attachment: AZ_acib_extension_of_joint_coll
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a research partnership between ArcticZymes Technologies ASA and the Austrian Centre of Industrial Biotechnology (acib) regarding enzyme use for bionanoparticle purification. It details the progress, future focus, and funding support (COMET program). This type of announcement, which is not a formal regulatory filing (like 10-K, IR, or ER) but rather a corporate update on strategic activities, partnerships, or research milestones, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'LTR' if it were about legal matters, but here it is clearly a business/research update. Given the options, RNS serves as the best catch-all for non-standard, yet important, corporate news releases that aren't explicitly covered by other codes like DIV, CAP, or MANG. The document length is short (3935 chars), but it is the primary content, not an announcement *of* another report, so RPA is not appropriate. It is a general corporate announcement.
2025-05-28 English
ArcticZymes and Austrian Centre of Industrial Biotechnology Extend Collaborative Research on use of Salt-Active Nucleases for Bionanoparticle Purification
Regulatory Filings Classification · 99% confidence The document announces an extension of a collaborative research partnership between ArcticZymes and the Austrian Centre of Industrial Biotechnology regarding enzyme use for bionanoparticle purification. It details research progress, future focus areas, funding (COMET program), and includes quotes from CEOs. This type of announcement, focusing on strategic partnerships, research milestones, and business development rather than routine financial results (ER, IR, 10-K) or specific shareholder actions (DIV, DVA), fits best under a general regulatory or corporate announcement category. Since it is not a formal financial report, earnings release, management discussion, or director dealing, and it is not explicitly announcing the publication of a major report (RPA), the most appropriate classification is Regulatory Filings (RNS) as a general corporate update/press release.
2025-05-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.